These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 22582973)

  • 21. Synthesis and biological evaluation of N-alkylated 8-oxybenz[c]azepine derivatives as selective PPARδ agonists.
    Luckhurst CA; Ratcliffe M; Stein L; Furber M; Botterell S; Laughton D; Tomlinson W; Weaver R; Chohan K; Walding A
    Bioorg Med Chem Lett; 2011 Jan; 21(1):531-6. PubMed ID: 21075629
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Discovery of novel PPAR ligands by a virtual screening approach based on pharmacophore modeling, 3D shape, and electrostatic similarity screening.
    Markt P; Petersen RK; Flindt EN; Kristiansen K; Kirchmair J; Spitzer G; Distinto S; Schuster D; Wolber G; Laggner C; Langer T
    J Med Chem; 2008 Oct; 51(20):6303-17. PubMed ID: 18821746
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Structure-based virtual screening and discovery of New PPARδ/γ dual agonist and PPARδ and γ agonists.
    Maltarollo VG; Togashi M; Nascimento AS; Honorio KM
    PLoS One; 2015; 10(3):e0118790. PubMed ID: 25767888
    [TBL] [Abstract][Full Text] [Related]  

  • 24. 1,3-Diphenyl-1H-pyrazole derivatives as a new series of potent PPARγ partial agonists.
    Choi J; Park Y; Lee HS; Yang Y; Yoon S
    Bioorg Med Chem; 2010 Dec; 18(23):8315-23. PubMed ID: 21030263
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Identification of novel PPARalpha ligands by the structural modification of a PPARgamma ligand.
    Usui S; Fujieda H; Suzuki T; Yoshida N; Nakagawa H; Miyata N
    Bioorg Med Chem Lett; 2006 Jun; 16(12):3249-54. PubMed ID: 16621530
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Structural insight into PPARgamma activation through covalent modification with endogenous fatty acids.
    Waku T; Shiraki T; Oyama T; Fujimoto Y; Maebara K; Kamiya N; Jingami H; Morikawa K
    J Mol Biol; 2009 Jan; 385(1):188-99. PubMed ID: 18977231
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Novel bisaryl substituted thiazoles and oxazoles as highly potent and selective peroxisome proliferator-activated receptor delta agonists.
    Epple R; Cow C; Xie Y; Azimioara M; Russo R; Wang X; Wityak J; Karanewsky DS; Tuntland T; Nguyêñ-Trân VT; Cuc Ngo C; Huang D; Saez E; Spalding T; Gerken A; Iskandar M; Seidel HM; Tian SS
    J Med Chem; 2010 Jan; 53(1):77-105. PubMed ID: 19928766
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Crystal structure of the peroxisome proliferator-activated receptor gamma (PPARgamma) ligand binding domain complexed with a novel partial agonist: a new region of the hydrophobic pocket could be exploited for drug design.
    Montanari R; Saccoccia F; Scotti E; Crestani M; Godio C; Gilardi F; Loiodice F; Fracchiolla G; Laghezza A; Tortorella P; Lavecchia A; Novellino E; Mazza F; Aschi M; Pochetti G
    J Med Chem; 2008 Dec; 51(24):7768-76. PubMed ID: 19053776
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Novel PPAR-gamma agonists identified from a natural product library: a virtual screening, induced-fit docking and biological assay study.
    Salam NK; Huang TH; Kota BP; Kim MS; Li Y; Hibbs DE
    Chem Biol Drug Des; 2008 Jan; 71(1):57-70. PubMed ID: 18086153
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Structure-based drug design of a novel family of PPARgamma partial agonists: virtual screening, X-ray crystallography, and in vitro/in vivo biological activities.
    Lu IL; Huang CF; Peng YH; Lin YT; Hsieh HP; Chen CT; Lien TW; Lee HJ; Mahindroo N; Prakash E; Yueh A; Chen HY; Goparaju CM; Chen X; Liao CC; Chao YS; Hsu JT; Wu SY
    J Med Chem; 2006 May; 49(9):2703-12. PubMed ID: 16640330
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CoMFA analysis of dual/multiple PPAR activators.
    Shah P; Mittal A; Bharatam PV
    Eur J Med Chem; 2008 Dec; 43(12):2784-91. PubMed ID: 18321611
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ombuin-3-O-β-D-glucopyranoside from Gynostemma pentaphyllum is a dual agonistic ligand of peroxisome proliferator-activated receptors α and δ/β.
    Malek MA; Hoang MH; Jia Y; Lee JH; Jun HJ; Lee DH; Lee HJ; Lee C; Lee MK; Hwang BY; Lee SJ
    Biochem Biophys Res Commun; 2013 Jan; 430(4):1322-8. PubMed ID: 23247028
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Synthesis, biological evaluation and molecular investigation of fluorinated peroxisome proliferator-activated receptors α/γ dual agonists.
    Fracchiolla G; Laghezza A; Piemontese L; Parente M; Lavecchia A; Pochetti G; Montanari R; Di Giovanni C; Carbonara G; Tortorella P; Novellino E; Loiodice F
    Bioorg Med Chem; 2012 Mar; 20(6):2141-51. PubMed ID: 22341573
    [TBL] [Abstract][Full Text] [Related]  

  • 34. PAM-1616, a selective peroxisome proliferator-activated receptor γ modulator with preserved anti-diabetic efficacy and reduced adverse effects.
    Kim MK; Chae YN; Choi SH; Moon HS; Son MH; Bae MH; Choi HH; Hur Y; Kim E; Park YH; Park CS; Kim JG; Lim JI; Shin CY
    Eur J Pharmacol; 2011 Jan; 650(2-3):673-81. PubMed ID: 20974124
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Discovery of highly potent and selective benzyloxybenzyl-based peroxisome proliferator-activator receptor (PPAR) delta agonists.
    Bratton LD; Filzen GF; Geyer A; Hoffman JK; Lu G; Pulaski J; Trivedi BK; Unangst PC; Xu X
    Bioorg Med Chem Lett; 2007 Jul; 17(13):3624-9. PubMed ID: 17498950
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Role of PPARalpha in mediating the effects of phthalates and metabolites in the liver.
    Lapinskas PJ; Brown S; Leesnitzer LM; Blanchard S; Swanson C; Cattley RC; Corton JC
    Toxicology; 2005 Feb; 207(1):149-63. PubMed ID: 15590130
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inflammatory reaction versus endogenous peroxisome proliferator-activated receptors expression, re-exploring secondary organ complications of spontaneously hypertensive rats.
    Sun L; Ke Y; Zhu CY; Tang N; Tian DK; Gao YH; Zheng JP; Bian K
    Chin Med J (Engl); 2008 Nov; 121(22):2305-11. PubMed ID: 19080338
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Activation of PPARdelta inhibits cardiac fibroblast proliferation and the transdifferentiation into myofibroblasts.
    Teunissen BE; Smeets PJ; Willemsen PH; De Windt LJ; Van der Vusse GJ; Van Bilsen M
    Cardiovasc Res; 2007 Aug; 75(3):519-29. PubMed ID: 17543901
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A PPARs cross-talk concertedly commits C6 glioma cells to oligodendrocytes and induces enzymes involved in myelin synthesis.
    Leisewitz AV; Urrutia CR; Martinez GR; Loyola G; Bronfman M
    J Cell Physiol; 2008 Nov; 217(2):367-76. PubMed ID: 18543250
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Three-in-one agonists for PPAR-α, PPAR-γ, and PPAR-δ from traditional Chinese medicine.
    Chen KC; Chang SS; Huang HJ; Lin TL; Wu YJ; Chen CY
    J Biomol Struct Dyn; 2012; 30(6):662-83. PubMed ID: 22731403
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.